During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Medically reviewed by Kelly Wood, MD The endocrine system is made of glands that produce hormones (chemical messengers), ...

Helene Lindfors, Ph.D. Student at the Endocrine Surgery research group, the Department of Molecular Medicine and Surgery, ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...

The approval for use in advanced neuroendocrine tumors is supported by data from the phase 3 CABINET trial (ClinicalTrials.gov Identifier: NCT03375320). The double-blind, placebo-controlled study ...

Stanley Tucci opened up about how his past radiation “burned out” his thyroid, leaving him “completely exhausted” several ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

Researchers demonstrate how breast cancer and its treatments contribute to accelerated aging in survivors. Breast cancer ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...